Pfizer INC Form 4 insider transactions

Executive Vice President Lidia Fonseca modifies stock appreciation rights (TSRUs) to extend their vesting and settlement dates by two years.

Pfizer's CEO, Albert Bourla, modified his stock appreciation rights (TSRUs) to extend the vesting and settlement dates by two years, according to a recent SEC filing.

Executive Vice President Rady A. Johnson modifies stock appreciation rights (SARs) and acquires phantom stock units in a recent transaction.

David M. Denton, CFO of Pfizer, modifies stock appreciation rights (TSRUs) to extend their vesting and settlement dates by two years.

Executive Vice President Michael McDermott modifies stock appreciation rights (SARs) to extend vesting and settlement dates.

Mikael Dolsten, President of R&D at Pfizer, modified stock appreciation rights (TSRUs) to extend their vesting and settlement dates by two years, as part of a company offer.

Executive Vice President Sally Susman modifies stock appreciation rights (SARs) in Pfizer, extending their vesting and settlement dates.

Executive Vice President Aamir Malik modifies stock appreciation rights (TSRUs) to extend their vesting and settlement dates by two years.

Payal Sahni, an Executive Vice President at Pfizer, modified stock appreciation rights (TSRUs) to extend their vesting and settlement dates by two years, as part of a one-time offer by the issuer.

Executive Vice President Douglas M. Lankler reports changes in beneficial ownership of Pfizer stock appreciation rights due to a modification offer.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., modifies stock appreciation rights (TSRUs) to extend the vesting and settlement dates by two years.

Executive Vice President Aamir Malik of Pfizer Inc. reports disposing of shares to cover tax obligations related to vesting restricted stock units.

Executive Vice President Rady A. Johnson reports acquiring phantom stock units in Pfizer through the Supplemental Savings Plan.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 18 phantom stock units through the Pfizer Supplemental Savings Plan on August 30, 2024.

Executive Vice President Rady A. Johnson reports acquiring 7 phantom stock units of Pfizer Inc. through the company's Supplemental Savings Plan.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reported the acquisition of 52 phantom stock units through the Pfizer Supplemental Savings Plan on August 15, 2024.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of phantom stock units through the company's Supplemental Savings Plan.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reported the sale of 5,154 shares of common stock at a price of $28.66 on August 13, 2024.

Pfizer Inc. reports the disposition of its Cerevel Therapeutics Holdings shares following the completion of the merger with AbbVie on August 1, 2024, where each share was converted to $45.00 in cash.

Executive Vice President Rady A. Johnson reports the acquisition of phantom stock units in Pfizer through the Supplemental Savings Plan.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reports the acquisition of phantom stock units through the Pfizer Supplemental Savings Plan.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 17 phantom stock units through the company's Supplemental Savings Plan on July 31, 2024.

Executive Vice President Rady A. Johnson reports acquiring phantom stock units in Pfizer through the company's Supplemental Savings Plan.

Jennifer B. Damico, SVP & Controller at Pfizer Inc., reported the acquisition of 52 phantom stock units through the Pfizer Supplemental Savings Plan on July 15, 2024.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 18 phantom stock units through the Pfizer Supplemental Savings Plan on July 15, 2024.

Executive Vice President Rady A. Johnson reports acquiring phantom stock units in Pfizer through the company's Supplemental Savings Plan.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reports the acquisition of 222 phantom stock units through the Pfizer Supplemental Savings Plan.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 71 phantom stock units through the company's Supplemental Savings Plan on July 11, 2024.

Director James C. Smith reports acquisition of phantom stock units representing deferred director's compensation.

Director James Quincey reports acquiring phantom stock units representing deferred director's compensation in Pfizer Inc.